Literature DB >> 18521857

Standardized protocol to identify high-risk patients undergoing therapeutic apheresis procedures.

Qun Lu1, Elena Nedelcu, Alyssa Ziman, Pam Bumerts, Leonor Fernando, Gary Schiller.   

Abstract

As the scope of therapeutic apheresis (TA) expands and more procedures are requested for critically ill patients, adverse reactions (AR) associated with TA become a major concern for physicians, nurses, patients and their families. To assess the risks for ARs associated with patients' underlying diseases, we developed a preprocedure assessment tool with a set of high-risk criteria which included: (1) unstable vital signs, (2) active nonphysiological bleeding, (3) evidence of severe bronchoconstriction, (4) severe anemia, (5) projected extracorporeal volume (ECV) >15% of total blood volume (TBV) in adults or >10% of TBV in pediatric patients, (6) pregnancy, and (7) conditions requiring continuous nursing support. A standard operating procedure with a "Request for Apheresis Procedure on High-Risk Patient" form and protocol were developed to identify patients as high-risk before initiation of a TA procedure. Here we report our experience in the 3-year period following the implementation of this protocol. During this period, a total of 3,254 TA procedures were performed, 44 of which were for patients identified as high-risk by the protocol. The incidence of overall ARs was 8% for all TA procedures and 45.5% for procedures performed for high-risk patients. The incidence of moderate-to-severe ARs was 3.7% for all TA procedures and 36.4% for procedures performed for high-risk patients. The protocol identified a group of patients with an increased risk for ARs, especially moderate-to-severe reactions during and/or immediately following TA. Copyright 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2008        PMID: 18521857     DOI: 10.1002/jca.20167

Source DB:  PubMed          Journal:  J Clin Apher        ISSN: 0733-2459            Impact factor:   2.821


  2 in total

1.  Decreasing frequency of plasma exchange complications in patients treated for thrombotic thrombocytopenic purpura-hemolytic uremic syndrome, 1996 to 2011.

Authors:  Sumit Som; Cassandra C Deford; Mandi L Kaiser; Deirdra R Terrell; Johanna A Kremer Hovinga; Bernhard Lämmle; James N George; Sara K Vesely
Journal:  Transfusion       Date:  2012-04-15       Impact factor: 3.157

2.  Standard operating procedures for clinical practice.

Authors:  T S Sathyanarayana Rao; Rajiv Radhakrishnan; Chittaranjan Andrade
Journal:  Indian J Psychiatry       Date:  2011-01       Impact factor: 1.759

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.